Lewis joins J. Calnan & Associates, Inc. as project executive, life sciences

September 07, 2018 - Owners Developers & Managers
Greg Lewis, JC&A

Quincy, MA J. Calnan & Associates, Inc. (JC&A) has hired industry veteran, Greg Lewis as a project executive, life sciences. 

JC&A is committed to maintaining its leadership position in the life sciences market. With more than 20 years of construction experience, Lewis has worked on a variety of projects from complex ground up construction projects, to major interior renovations, to the development of biotech/life science campuses for manufacturing, laboratory and office space as well as LEED certified projects. He has held leadership positions in real estate planning at Shire Pharmaceuticals, Wyeth Pharmaceuticals (now Pfizer) and Millennium Pharmaceuticals (now Takeda). He has also worked on the service provider side as the vice president, sector head, life sciences for STV | DPM where he managed teams for clients such as Sanofi Genzyme, Pfizer, Shire, AstraZeneca, Tesaro, Ipsen, Amgen, Ariad, Genocea and a host of startups. The rapid growth of these companies has left him with a keen understanding and knowledge of the sustainable working environments as well as expertise in facilities operations in this specialized sector. 

President and partner of JC&A, Jim Cahill said, “We have known Greg for years as our client and a personal friend through our work together at Wyeth Pharmaceuticals (now Pfizer), Shire Pharmaceuticals and Takeda as well as through events within the industry. He is well respected within the industry and has a keen understanding of all the nuances involved in the Life Sciences market, shares in our company values and is a great addition to our team. We are excited to have him at JC&A, and are confident his skillset, knowledge and network will further enhance our leadership position within life sciences.”

Lewis will work closely with Brian Mikolaycik, senior manager of life sciences who has been involved with many of the complex projects within life sciences, including multiple projects for Agilent Technologies, Alexion Pharmaceuticals, Lantheus, Takeda Pharmaceuticals, Acceleron Pharmaceuticals and Servomex to name a few.

Comments

Add Comment


More from the New England Real Estate Journal